Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes

NCT03646292 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03646292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03646292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes
Lead sponsor
Yonsei University
Phase
Phase 4
Overall status
Completed
Start date
December 6, 2018
Completion date
June 16, 2022
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system disease, empagliflozin, fatty liver, hypoglycemic agents, liver diseases, masld - metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, molecular mechanisms of pharmacological action, non-alcoholic fatty liver disease, physiological effects of drugs, pioglitazone, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, type 2 diabetes